⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MGTX News
MeiraGTx Holdings plc Ordinary Shares
Form 8-K
sec.gov
MGTX
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
globenewswire.com
MGTX
JNJ
Form 8-K
sec.gov
MGTX
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
globenewswire.com
MGTX
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
globenewswire.com
MGTX
Form 8-K
sec.gov
MGTX
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
globenewswire.com
MGTX
LLY
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
globenewswire.com
SUPN
MGTX
JNJ
ARWR
ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
prnewswire.com
MGTX
Marengo to Present Initial Results from Invikafusp Alfa and TRODELVY® Combination Study, STARt-002, at the 2025 San Antonio Breast Cancer Symposium
prnewswire.com
GILD
MGTX